Home>Topics>Stocks>Valeant Pharmaceuticals International

Valeant Pharmaceuticals International VRX

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Valeant in talks to buy Egyptian drugmaker Amoun Pharma-Bloomberg

      Headlines

      Wed, 20 May 2015

      May 20 (Reuters) - Valeant Pharmaceuticals International Inc is in talks to buy Egyptian drugmaker Amoun Pharmaceutical Co to expand its veterinary and human medicines portfolio, Bloomberg reported, citing people familiar with the matter.

    2. Valeant CEO expects sharp rise in Asia revenue by 2020

      Headlines

      Tue, 19 May 2015

      MONTREAL, May 19 (Reuters) - Valeant Pharmaceuticals International Inc's exposure to Asia's growing middle class could help lead to the quintupling of sales in that market to around $5 billion by...

    3. Big name investors take sides on Ackman bet on Valeant: filings

      Headlines

      Fri, 15 May 2015

      BOSTON (Reuters) - Wall Street's savviest investors are picking sides on Bill Ackman's new bet on Valeant Pharmaceuticals International Inc , with BlueMountain Capital and T. Rowe Price adding money, while Viking Global Investors and Jana Partners cut stakes.

    4. Big name investors take sides on Ackman bet on Valeant -filings

      Headlines

      Fri, 15 May 2015

      BOSTON, May 15 (Reuters) - Wall Street's savviest investors are picking sides on Bill Ackman's new bet on Valeant Pharmaceuticals International Inc, with BlueMountain Capital and T. Rowe Price adding money, while Viking Global Investors and Jana Partners cut stakes.

    5. From Barron’s, May 11, 2015 (Part 2)

      Commentary

      Sat, 9 May 2015

      BRK-A/B ] to Pearson ’s Valeant [ VRX ]. The entire piece is devoted to disputing ..... cheaper than rather expensive and volatile VRX . Pg 14-15: BOE rate announcement on Monday. Euro ..... frackers ok] Ackman / Pershing Square : VRX [also see Levisohn/Pg 11 above] Gaonkar / Lone

    6. Confessions of an Average Investor

      Commentary

      Sat, 9 May 2015

      went to the individual holdings of PRHSX. Some of my contenders were: TR 10 yr 15yr GILD 26.87% 29.71% Nope no yield VRX 30.84% 15.53% Nope no yield ALXN 40.44% 19.21% Nope no yield PCYC 42.80% 12.91% Nope no yield I could go on

    7. From Barron’s, May 4, 2015 (Part 1)

      Commentary

      Sat, 2 May 2015

      based on 3-yr cash flow returns on investments [CFROI], 1-yr change in CFROI, and sales growth. Top 5: GLD, CBG, VRX , TMO, MA . Bottom 5: CVX, SHLD, APA, TCK, NEM, ABX . Cheapest 5 [lowest P/E]: AAL, UAL, TRN, PPC, PBF More later

    8. UPDATE 2-Drugmaker Valeant raises forecasts, says CFO to leave

      Headlines

      Wed, 29 Apr 2015

      April 29 (Reuters) - Drugmaker Valeant Pharmaceuticals International Inc raised its earnings and sales forecasts for the year on Wednesday and said its chief financial officer will step down.

    9. Valeant Pharma posts profit, says CFO to step down

      Headlines

      Wed, 29 Apr 2015

      April 29 (Reuters) - Canadian drugmaker Valeant Pharmaceuticals International Inc reported a quarterly profit, compared with a year-ago loss, driven by higher demand in the United States.

    10. Global Diabetic Retinopathy Market 2015 - Global Market Size, Trends, Development, and Forecasts to 2019

      Commentary

      Tue, 21 Apr 2015

      F. Hoffmann-La Roche Ltd. - Novartis AG - Pfizer Inc. - Regeneron Pharmaceuticals Inc. - Valeant Pharmaceuticals International Inc. Other Prominent Vendors - Abbott Laboratories Ltd. - Alcon Laboratories Inc. - Alimera Sciences

    « Prev12345Next »
    Content Partners